Surabhi Uppal1, Mohanad Hadi2, Sheetal Chhaya3,4. 1. Department of Internal Medicine, St. Joseph's Hospital and Medical Center, 500 W. Thomas Road, Phoenix, AZ, 85013, USA. 2. Maricopa Integrated Health Systems, Division of Rheumatology, Comprehensive Health Center, 2525 East Roosevelt St, Phoenix, AZ, 85008, USA. 3. Maricopa Integrated Health Systems, Division of Rheumatology, Comprehensive Health Center, 2525 East Roosevelt St, Phoenix, AZ, 85008, USA. Chhayash4@gmail.com. 4. , Paradise Valley, USA. Chhayash4@gmail.com.
Abstract
PURPOSE OF REVIEW: Giant cell arteritis is a systemic large vessel vasculitis that affects the older population and can cause progressive and at times, devastating complications including vision loss. While this has been commonly diagnosed and treated among vasculitides, the treatment options are limited and can have long-term adverse effects. The purpose of our review on GCA is to identify and discuss the pathophysiology and clinical aspects of GCA as they relate to the most recent data. The review will describe any new data on the diagnosis and treatment of this systemic large vessel vasculitis. RECENT FINDINGS: The latest data suggests that the mainstay of treatment of GCA remains glucocorticoids but alternate agents are being identified and used in an attempt to reduce the cumulative exposure to glucocorticoids and reduce treatment-related adverse effects while managing and maintaining remission of this systemic disease. There is much more information to collect in terms of identification and standardization of the optimal length of time to treat with glucocorticoids as well as regarding the long-term efficacy of alternate treatments. In addition, investigation continues to identify measureable risk factors to predict outcomes of individual patients with this diagnosis.
PURPOSE OF REVIEW: Giant cell arteritis is a systemic large vessel vasculitis that affects the older population and can cause progressive and at times, devastating complications including vision loss. While this has been commonly diagnosed and treated among vasculitides, the treatment options are limited and can have long-term adverse effects. The purpose of our review on GCA is to identify and discuss the pathophysiology and clinical aspects of GCA as they relate to the most recent data. The review will describe any new data on the diagnosis and treatment of this systemic large vessel vasculitis. RECENT FINDINGS: The latest data suggests that the mainstay of treatment of GCA remains glucocorticoids but alternate agents are being identified and used in an attempt to reduce the cumulative exposure to glucocorticoids and reduce treatment-related adverse effects while managing and maintaining remission of this systemic disease. There is much more information to collect in terms of identification and standardization of the optimal length of time to treat with glucocorticoids as well as regarding the long-term efficacy of alternate treatments. In addition, investigation continues to identify measureable risk factors to predict outcomes of individual patients with this diagnosis.
Authors: P Chevalet; J H Barrier; P Pottier; G Magadur-Joly; M A Pottier; M Hamidou; B Planchon; D El Kouri; L Connan; J L Dupond; B De Wazieres; G Dien; E Duhamel; B Grosbois; P Jego; A Le Strat; J Capdeville; P Letellier; L Agron Journal: J Rheumatol Date: 2000-06 Impact factor: 4.666
Authors: Miguel A Gonzalez-Gay; Sonia Barros; Maria J Lopez-Diaz; Carlos Garcia-Porrua; Amalia Sanchez-Andrade; Javier Llorca Journal: Medicine (Baltimore) Date: 2005-09 Impact factor: 1.889
Authors: R F Spiera; H J Mitnick; M Kupersmith; M Richmond; H Spiera; M G Peterson; S A Paget Journal: Clin Exp Rheumatol Date: 2001 Sep-Oct Impact factor: 4.473
Authors: J A Jover; C Hernández-García; I C Morado; E Vargas; A Bañares; B Fernández-Gutiérrez Journal: Ann Intern Med Date: 2001-01-16 Impact factor: 25.391
Authors: M A González-Gay; C García-Porrúa; J Llorca; A H Hajeer; F Brañas; A Dababneh; C González-Louzao; E Rodriguez-Gil; P Rodríguez-Ledo; W E Ollier Journal: Medicine (Baltimore) Date: 2000-09 Impact factor: 1.889
Authors: Gary S Hoffman; Maria C Cid; Karen E Rendt-Zagar; Peter A Merkel; Cornelia M Weyand; John H Stone; Carlo Salvarani; Weichun Xu; Sudha Visvanathan; Mahboob U Rahman Journal: Ann Intern Med Date: 2007-05-01 Impact factor: 25.391
Authors: Gary S Hoffman; Maria C Cid; David B Hellmann; Loic Guillevin; John H Stone; John Schousboe; Pascal Cohen; Leonard H Calabrese; Howard Dickler; Peter A Merkel; Paul Fortin; John A Flynn; Geri A Locker; Kirk A Easley; Eric Schned; Gene G Hunder; Michael C Sneller; Carol Tuggle; Howard Swanson; J Hernández-Rodríguez; Alfons Lopez-Soto; Debora Bork; Diane B Hoffman; Kenneth Kalunian; David Klashman; William S Wilke; Raymond J Scheetz; Brian F Mandell; Barri J Fessler; Gregory Kosmorsky; Richard Prayson; Raashid A Luqmani; George Nuki; Euan McRorie; Yvonne Sherrer; Shawn Baca; Bridgit Walsh; Diane Ferland; Martin Soubrier; Hyon K Choi; Wolfgang Gross; Allen M Segal; Charles Ludivico; Xavier Puechal Journal: Arthritis Rheum Date: 2002-05